Creative Medical Technology Holdings, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
Creative Medical Technology Holdings, Inc. (CELZ) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $286.41 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2020-05-15
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2020-03-31 was $286.41K, a 69.05% decline year-over-year.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2019-12-31 was $1.17M, a 175.92% increase year-over-year.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2019-09-30 was $539.40K, a 22.14% decline year-over-year.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2019-06-30 was -$142.02K, a 108.81% decline year-over-year.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2019 was $2.49M, a 31.42% decline from fiscal 2018.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2018 was $3.63M, a 250.45% increase from fiscal 2017.
- Creative Medical Technology Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2017 was $1.04M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|---|
| 2020-03-31 | $286.41K 10-Q · filed 2020-05-15 | $1.45M derived: sum of 2 quarters · filed 2020-05-15 | $1.99M derived: sum of 3 quarters · filed 2020-05-15 | $1.85M derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-06 | $1.70M derived: sum of 2 quarters · filed 2020-04-06 | $1.56M derived: sum of 3 quarters · filed 2020-04-06 | $2.49M 10-K · filed 2020-04-06 |
| 2019-09-30 | $539.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $397.39K derived: sum of 2 quarters · filed 2019-11-14 | $1.32M 10-Q · filed 2019-11-14 | $1.74M derived: sum of 4 quarters · filed 2019-11-14 |
| 2019-06-30 | -$142.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $783.31K 10-Q · filed 2019-08-13 | $1.21M derived: sum of 3 quarters · filed 2019-08-13 | $1.90M derived: sum of 4 quarters · filed 2019-08-13 |
| 2019-03-31 | $925.33K 10-Q · filed 2019-05-20 | $1.35M derived: sum of 2 quarters · filed 2019-05-20 | $2.04M derived: sum of 3 quarters · filed 2019-05-20 | $3.65M derived: sum of 4 quarters · filed 2019-05-20 |
| 2018-12-31 | $422.24K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $1.12M derived: sum of 2 quarters · filed 2019-04-01 | $2.73M derived: sum of 3 quarters · filed 2019-04-01 | $3.63M 10-K · filed 2019-04-01 |
| 2018-09-30 | $692.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $2.30M derived: sum of 2 quarters · filed 2018-11-14 | $3.21M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $2.51M 10-Q · filed 2018-08-14 | ||
| 2018-03-31 | $900.77K 10-Q · filed 2018-08-03 | |||
| 2017-12-31 | $1.04M 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |